In the Claims:

1. (Currently Amended) A compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof in which:

X is selected from the group consisting of oxygen or NR^2;

R^1 is selected from the group consisting of H, C_{1-6}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-10}cycloalkylC_{0-6}alkyl, C_{4-12}bridged cycloalkyl, $A(CR^5R^6)_n$ and $B(CR^5R^6)_n$;

R^2 is selected from the group consisting of H and C_{1-6}alkyl;

R^3 is C_{1-2}alkyl substituted by one to five fluorine atoms;

R^4 is selected from the group consisting of C_{1-6}alkyl, NH_2 and R^8CONH;

R^5 and R^6 are independently selected from H or C_{1-6}alkyl;

A is an unsubstituted 5- or 6-membered heteroaryl or an unsubstituted 6-membered aryl, or a 5- or 6-membered heteroaryl or a 6-membered aryl substituted by one or more R^7;

R^7 is selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-6}alkyl substituted by one more fluorine atoms, C_{1-6}alkoxy, C_{1-6}alkoxy substituted by one or more F, NH_2SO_2 and C_{1-6}alkylSO_2;

B is selected from the group consisting of



and where

) defines the point of attachment of the ring;

R^8 is selected from the group consisting of H, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}alkylOC_{1-6}alkyl, phenyl, HO_2CC_{1-6}alkyl, C_{1-6}alkyl$OCOC_{1-6}$alkyl,

C_{1-6}alkylOCO, H_2NC_{1-6}alkyl, C_{1-6}alkylOCONHC_{1-6}alkyl and C_{1-6}alkylCONHC_{1-6}alkyl; and

n is 0 to 4,

wherein the 5-membered heteroaryl is selected from



and

wherein the 6-membered heteroaryl is selected from



2. (Currently Amended) A compound of formula (IA)



(IA)

or a pharmaceutically acceptable salt thereof in which:

R^2 is selected from the group consisting of H and C_{1-6}alkyl;

R^4 is selected from the group consisting of C_{1-6}alkyl, NH_2 and R^8CONH;

R^5 and R^6 are independently selected from H or C_{1-6}alkyl;

A is C_{5-7}cycloalkyl or an unsubstituted 5- or 6-membered heteroaryl or an unsubstituted 6-membered aryl, or a 5- or 6-membered heteroaryl or a 6-membered aryl substituted by one or more R^7;

R^7 is selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-6}alkyl substituted by one more fluorine atoms, C_{1-6}alkoxy, C_{1-6}alkoxy substituted by one or more F, NH_2SO_2 and C_{1-6}alkylSO_2;

R^8 is selected from the group consisting of H, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}alkylOC_{1-6}alkyl, phenyl, HO_2CC_{1-6}alkyl, C_{1-6}alkyl$OCOC_{1-6}$alkyl, C_{1-6}alkylOCO, H_2NC_{1-6}alkyl, C_{1-6}alkyl$OCONHC_{1-6}$alkyl and C_{1-6}alkyl$CONHC_{1-6}$alkyl; and

n is 0 to 4,

wherein the 5-membered heteroaryl is selected from



and

wherein the 6-membered heteroaryl is selected from



3. (Previously Presented) A compound as claimed in claim 1 wherein R^2 is H or methyl.

4. (Previously Presented) A compound as claimed in claim 1 wherein R^4 is C_{1-3}alkyl.

5. (Previously Presented) A compound as claimed in claim 1 wherein R^5 and R^6 are both H.

6. (Previously Presented) A compound as claimed in claim 1 wherein A is selected from the group consisting of C_{5-7}cycloalkyl or



where

) defines the point of attachment of the ring

and A is unsubstituted or substituted by one or two R^7.

7. (Previously Presented) A compound as claimed in claim 1 wherein R^7 is selected from the group consisting of halogen, C_{1-3}alkyl, C_{1-3}alkyl substituted by one to three fluorine atoms, and C_{1-3}alkoxy.

8. (Previously Presented) A compound as claimed in claim 1 wherein R^8 is selected from the group consisting of C_{1-6}alkyl, phenyl and aminomethyl.

9. (Previously Presented) A compound as claimed in claim 1 wherein n is 0 to 2.

10. (Canceled).

11. (Previously Presented) [4-(5-Methanesulfonyl-pyridin-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-methyl-(6-methyl-pyridin-2-ylmethyl)-amine; benzyl-[4-(5-methanesulfonyl-pyridin-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-amine; and cyclohexyl-[4-(5-methanesulfonyl-pyridin-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-amine.

12. (Currently Amended) A process for the preparation of a compound as defined in claim 1, which comprises:

(A), reacting a compound R^1XH ~~of formula (II)~~ or a protected derivative thereof with a compound of formula (III)



(III)

wherein R^3 and R^4 are as defined in claim 1, to produce a compound of formula (I)

and thereafter and if necessary,

(B), interconverting the ~~a~~ compound of formula (I) into another compound of formula (I); and/or

(C), deprotecting a protected derivative of compound of formula (I).

13. (Currently Amended) A process for the preparation of a compound as defined in claim 2, which comprises:

(A) reacting an amine $HNR^2(CR^5R^6)_nA$ ~~of formula (IIA)~~ or a protected derivative thereof with a compound of formula (III) wherein R^3 is CF_3



(III)

wherein R^4 is as defined in claim 2, to produce a compound of formula (IA),

and thereafter and if necessary,

(B), interconverting the ~~a~~ compound of formula (IA) into another compound of formula (I); and/or

(C), deprotecting a protected derivative of compound of formula (IA).

14. (Previously Presented) A pharmaceutical composition comprising a compound as defined in claim 1 in admixture with one or more physiologically acceptable carriers or excipients.

15.-19. (Cancelled)

20. (Previously Presented) A pharmaceutical composition comprising a compound as defined in claim 2 in admixture with one or more physiologically acceptable carriers or excipients.

21.- 22. (Canceled)

23. (New) A method of treating a subject suffering from acute or chronic pain which comprises administering to said subject an effective amount of a compound as claimed in claim 1.

24. (New) The method according to claim 23, wherein said subject is a human.

25. (New) A method of treating a subject suffering from dysmenorrhoea which comprises administering to said subject an effective amount of a compound as claimed in claim 1.

26. (New) The method according to claim 25, wherein said subject is a human.

27. (New) A method of treating a subject suffering from arthritis which comprises administering to said subject an effective amount of a compound as defined in claim 1.

28. (New) The method according to claim 27 wherein said arthritis is rheumatoid arthritis.

29. (New) The method according to claim 28 wherein said subject is a human.

30. (New) A method of treating a subject suffering from osteoarthritis which comprises administering to said subject an effective amount of a compound as defined in claim 1.

31. (New) The method according to claim 30 wherein said subject is a human

32. (New) A method of treating a subject suffering from acute or chronic pain which comprises administering to said subject an effective amount of a compound as claimed in claim 2.

33. (New) The method according to claim 32, wherein said subject is a human.

34. (New) A method of treating a subject suffering from dysmenorrhoea which comprises administering to said subject an effective amount of a compound as claimed in claim 2.

35. (New) The method according to claim 34, wherein said subject is a human.

36. (New) A method of treating a subject suffering from arthritis which comprises administering to said subject an effective amount of a compound as defined in claim 2.

37. (New) The method according to claim 36 wherein said arthritis is rheumatoid arthritis.

38. (New) The method according to claim 36 wherein said subject is a human.

39. (New) A method of treating a subject suffering from osteoarthritis which comprises administering to said subject an effective amount of a compound as defined in claim 2.

40. (New) The method according to claim 39 wherein said subject is a human.